Clinical Trial Results:
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled trial of
Ustekinumab, a Fully Human anti-IL-12/23p40 Monoclonal Antibody,
Administered Subcutaneously, in Subjects with Active Psoriatic Arthritis Including Those Previously Treated with Biologic Anti-TNFα Agent(s)
Summary
|
|
EudraCT number |
2009-012265-60 |
Trial protocol |
AT DE SE FR GB PL HU |
Global completion date |
15 Nov 2012
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v2(current) |
This version publication date |
23 Oct 2016
|
First version publication date |
04 Jun 2016
|
Other versions |
v1 |
Version creation reason |
|
Summary report(s) |
CNTO1275PSA3002 _2009-012265-60_CSR Synopsis.pdf |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.